InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-2.8%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Hagen Heidi, Director. Insider active across 2 companies, notably Vericel Corp. Cumulatively, 10 reports have been logged. Breakdown: 2 buys · 0 sell. Total volume traded: €70k. Activity tracked since 19 May 2021. The latest transaction was filed on 3 March 2025 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations10 total
3,200 sharesCommon StockSEC:0001140361-25-017118:0
9,000 shares@ US$3.7453.1% of flowCommon StockSEC:0001140361-25-007181:0
4,000 shares@ US$3.7422.7% of flowCommon StockSEC:0001140361-24-043798:0
3,200 sharesCommon StockSEC:0001140361-24-024331:0
2,600 sharesCommon StockSEC:0001140361-23-021498:0
2,600 sharesCommon StockSEC:0001593968-22-000888:0
23,770 shares@ US$1.7650.0% of flowCommon StockSEC:0001209191-21-054829:0
Ideal exit: 30 May 2022 (T+270)
23,770 shares@ US$1.7650.0% of flowCommon StockSEC:0001209191-21-054829
Ideal exit: 30 May 2022 (T+270)
1,500 shares@ US$6.0050.0% of flowCommon StockSEC:0001593968-21-001389
1,500 shares@ US$6.000.0004% mcap50.0% of flowCommon StockSEC:0001593968-21-001389:0
10 of 10 declarations
About Hagen Heidi
Heidi Hagen is a Board Member at Vericel Corp and ZIOPHARM ONCOLOGY INC. She plays an important role in the governance of these companies, bringing her expertise in strategy and management. As a board member, she participates in strategic decision-making and guides the companies toward a sustainable future.
